Blog
Daily evidence-led peptide research, regulatory news, expert digest and explainers. Every claim sourced; no AI tells.
Page 83
CJC-1295/Ipamorelin 10 mg Blend Dosing
How to calculate the dose from a CJC-1295/ipamorelin 10 mg blend vial. Step-by-step reconstitution math and what the research actually supports.
CJC-1295 and Ipamorelin Hives Explained
Hives at old CJC-1295 and ipamorelin injection sites are usually mast-cell driven, not a true allergy. Here is what the literature says.
Dulaglutide in 2026: still relevant?
A narrative review argues dulaglutide still earns its place in cardiometabolic care despite tirzepatide and semaglutide gaining ground.
Dupuytren's contracture and peptides
Dupuytren's contracture surfaces in peptide forums alongside GLP-1 drugs. The biological overlap with fibrotic pathways is real. The direct evidence is not.
GLP-1 add-on doubled time in range: Ramadan
A 2026 CGM study found that adding semaglutide or tirzepatide to insulin doubled time in range during Ramadan fasting without raising hypoglycaemia risk.
GLP-1 drugs and knee replacement risk
A large retrospective study ties GLP-1 receptor agonist use to lower rates of knee replacement surgery for osteoarthritis.
GLP-1 drugs cut CV risk in type 2 diabetes
A 2026 network meta-analysis finds GLP-1 therapies reduce mortality and MACE in type 2 diabetes. Semaglutide and albiglutide rank highest.
GLP-1 drugs and hair loss: the data
Hair loss affects roughly 4% of GLP-1 receptor agonist users. The likely cause is rapid weight loss triggering telogen effluvium, not direct follicle damage.
GLP-1 drugs tied to lower heart risk in RA
A TriNetX cohort study found GLP-1 therapy halved heart failure and respiratory failure risk in non-diabetic adults with RA and obesity.
Do GLP-1 drugs reduce fat graft survival?
A scoping review flags several mechanisms through which GLP-1 receptor agonists may reduce fat graft survival. No clinical data exist yet.
Ipamorelin 3x a day: what the evidence says
No human trial has tested a three-times-daily ipamorelin protocol. Here is where the idea comes from and what is missing from the evidence.
IWQOL-Lite-CT: trial vs real-world scores
Real-world adults with obesity score far worse on the IWQOL-Lite-CT than STEP 1 semaglutide trial participants. The instrument works, but baselines differ.